产品
编 号：F755944
分子式：C19H18N3O2PS
分子量：383.4
分子式：C19H18N3O2PS
分子量：383.4
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 2772600-18-5
产品详情
生物活性：
Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis.
体内研究：
Zharp2-1（15 mg/kg；灌胃；每天一次，持续 6 天）可保护大鼠免受 DNBS 诱导的结肠缩短和结肠重量增加，保护大鼠免受 DNBS 诱导的腹泻。Zharp2-1 显著改善结肠粘膜结构破坏、肌肉增厚和炎症浸润。药代动力学分析RouteDose (mg/kg)T1/2 (h)Tmax (h)Cmax (ng·h/mL)AUC (ng·h/mL)Vd (L/kg)Cl (mL/kg/min)F (%)
Mouseiv21.229891.111.1
po100.5961019,236129
Rativ21.778890.64.2
po103.3332318,80348
Dogiv12.116451.79.5
po50.7219210,800131
体外研究：
Zharp2-1 (IC50=6.4-17.4 nM; 2 h) 预处理 THP-1 和 iBMDM 细胞，并抑制 10 μg/mL MDP 或 1 μg/mL L18-MDP 诱导 12 小时后引起的 IL-6 和 TNF-α 释放。
Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis.
体内研究：
Zharp2-1（15 mg/kg；灌胃；每天一次，持续 6 天）可保护大鼠免受 DNBS 诱导的结肠缩短和结肠重量增加，保护大鼠免受 DNBS 诱导的腹泻。Zharp2-1 显著改善结肠粘膜结构破坏、肌肉增厚和炎症浸润。药代动力学分析RouteDose (mg/kg)T1/2 (h)Tmax (h)Cmax (ng·h/mL)AUC (ng·h/mL)Vd (L/kg)Cl (mL/kg/min)F (%)
Mouseiv21.229891.111.1
po100.5961019,236129
Rativ21.778890.64.2
po103.3332318,80348
Dogiv12.116451.79.5
po50.7219210,800131
体外研究：
Zharp2-1 (IC50=6.4-17.4 nM; 2 h) 预处理 THP-1 和 iBMDM 细胞，并抑制 10 μg/mL MDP 或 1 μg/mL L18-MDP 诱导 12 小时后引起的 IL-6 和 TNF-α 释放。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备